[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Patonay P, Naszály A, Mayer A, Pócza K, Kovács L: [Radio-chemotherapy for non-resectable primary esophageal malignant melanoma]. Magy Onkol; 2004;48(4):303-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radio-chemotherapy for non-resectable primary esophageal malignant melanoma].
  • [Transliterated title] Irreszekábilis elsôdleges nyelôcsô melanoma malignum radiokemoterápiája.
  • AIM: to demonstrate the simultaneous radio-chemotherapy of primary esophageal malignant melanoma on the basis of one case.
  • PATIENT AND METHODS: 68-years-old male patient with malignant melanoma in middle part of the esophagus.
  • The therapy was started with intraluminal high-dose-rate afterloading brachytherapy for the recanalisation of the esophagus (8 Gy in 0.5 cm deep), followed by percutaneous megavolt therapy two weeks after the last HDR AL session (50 Gy total dose, 5 x 2 Gy/week fractions for 5 week, 3D conformal planning).
  • The chemotherapy was started simultaneously with the percutaneous megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, repeated in four-week intervals).
  • After the radio-chemotherapy a supraclavicular metastasis was verified, so the radio-chemotherapy was followed with megavolt therapy of the metastasis at 30 Gy dose (5 x 2 Gy/week fractions), and chemotherapy (Cisplatin-Dacarbazine combination in 6-session, four-week intervals) and after them immunotherapy was started.
  • After the beginning of the radio-chemotherapy the swallow function was good for 16 months, and 18 months after the beginning of radio-chemotherapy the patient died due to pulmonary and hepatic dissemination.
  • CONCLUSION: Radio-chemotherapy of esophageal malignant melanoma has favorable palliative effect with acceptable quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Melanoma / drug therapy. Melanoma / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Palliative Care / methods. Quality of Life. Radiotherapy Dosage. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655575.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Gupta V, Kochhar R, Sinha SK, Das A: Primary malignant melanoma of the esophagus: long-term survival after radical resection. J Thorac Oncol; 2009 Sep;4(9):1180-2
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus: long-term survival after radical resection.
  • Endoscopy revealed a large polypoidal pedunculated blackish mass located in the lower thoracic esophagus.
  • A barium esophagogram revealed a lower esophageal mass.
  • Computed tomography revealed a large polypoidal esophageal mass without any evidence of local invasion or distant disease.
  • Endoscopic biopsy established the diagnosis of melanoma.
  • A radical resection of the esophagus with three-field lymph nodal dissection was undertaken.
  • Histopathology confirmed the diagnosis of melanoma and positive lymph nodes.
  • Adjuvant chemotherapy was given.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704341.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Terada T: Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA. World J Gastroenterol; 2009 Jun 7;15(21):2679-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma of the esophagus: report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRA.
  • The author reports herein two cases of amelanotic malignant melanoma of the esophagus.
  • Endoscopic examination revealed an ulcerated tumor of the distal esophagus, and a biopsy was taken.
  • The patient was treated by chemotherapy and radiation, but died of systemic metastasis 12 mo after the presentation.
  • Endoscopic examination revealed a polypoid tumor in the middle esophagus, and a biopsy was obtained.
  • The patient refused operation, and was treated by palliative chemotherapy and radiation.
  • This is the first report of esophageal malignant melanoma with an examination of the expression of KIT and PDGFRA and the mutational status of KIT and PDGFRA genes.
  • [MeSH-major] Esophageal Neoplasms. Melanoma, Amelanotic. Receptor, Platelet-Derived Growth Factor alpha / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 2005 Jun;43(6):597-600 [15986290.001]
  • [Cites] Hum Pathol. 2005 May;36(5):486-93 [15948115.001]
  • [Cites] Melanoma Res. 2005 Aug;15(4):251-6 [16034302.001]
  • [Cites] Melanoma Res. 2005 Aug;15(4):283-5 [16034306.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):205-20 [16082245.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Minerva Chir. 2006 Feb;61(1):45-9 [16568022.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):1102-10 [16410786.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1207-10 [17040443.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] J Cutan Pathol. 2007 Jan;34(1):7-14 [17214848.001]
  • [Cites] Melanoma Res. 2007 Aug;17(4):239-42 [17625454.001]
  • [Cites] J Invest Dermatol. 2008 Feb;128(2):488-9 [17762857.001]
  • [Cites] Pathol Int. 2008 Jul;58(7):432-5 [18577112.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1623-9 [18834221.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6821-8 [18980976.001]
  • [Cites] Pathol Int. 2008 Dec;58(12):801-5 [19067857.001]
  • [Cites] Pathol Int. 2008 Dec;58(12):806-9 [19067858.001]
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7256-9 [19084944.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):29-34 [19047911.001]
  • [Cites] Pathol Int. 2009 Jan;59(1):53-8 [19121093.001]
  • [Cites] Pathol Int. 2009 Apr;59(4):247-50 [19351368.001]
  • [Cites] Med Oncol. 2009;26(2):233-7 [18777214.001]
  • [Cites] Med Oncol. 2009;26(2):247-50 [18989797.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):595-601 [14646623.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):116-23 [14720143.001]
  • [Cites] J Surg Oncol. 1979;12(1):19-25 [113625.001]
  • [Cites] Jpn J Clin Oncol. 1990 Sep;20(3):286-95 [2255105.001]
  • [Cites] Gastroenterol Jpn. 1991 Apr;26(2):209-12 [2040402.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Jpn J Clin Oncol. 1991 Aug;21(4):306-13 [1942560.001]
  • [Cites] Mod Pathol. 1997 Sep;10(9):939-44 [9310959.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Int J Clin Oncol. 2005 Jun;10(3):204-7 [15990972.001]
  • (PMID = 19496203.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC2691504
  •  go-up   go-down


Advertisement
4. Matsutani T, Onda M, Miyashita M, Hagiwara N, Akiya Y, Takubo K, Yamashita K, Sasajima K: Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy. Dis Esophagus; 2001;14(3-4):241-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.
  • We describe herein a case of asymptomatic primary malignant melanoma of the esophagus.
  • A 65-year-old man presented with a 4-cm filling defect in the middle third of the esophagus on a routine barium swallow.
  • Postoperatively, the patient received five cycles of systemic chemotherapy with dacarbazine (DTIC), nimustine hydrochloride (ACNU), and vincristine (VCR) (DAV therapy), but ultimately died of generalized metastatic disease 15 months after surgery.
  • Malignant melanoma of the esophagus has an extremely poor prognosis despite various therapeutic efforts.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11869329.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


5. Li B, Lei W, Shao K, Zhang C, Chen Z, Shi S, He J: Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res; 2007 Aug;17(4):239-42
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and prognosis of primary malignant melanoma of the esophagus.
  • Primary malignant melanoma of the esophagus is an extremely rare but highly aggressive tumor.
  • Unfortunately, the prognosis of primary malignant melanoma of the esophagus remains dismal from most literatures.
  • To better understand this special condition, we reviewed the medical records of patients with primary malignant melanoma of the esophagus in our center, retrospectively.
  • Similar to esophageal carcinoma, dysphagia was the most common symptom.
  • Only one patient, however, was pathologically diagnosed as primary malignant melanoma of the esophagus preoperatively.
  • Our data show that primary malignant melanoma of the esophagus is a highly aggressive disease with poor prognosis.
  • Surgery remains the first selected therapy.
  • The role of radiotherapy and chemotherapy in the treatment of primary malignant melanoma of the esophagus is still uncertain.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625454.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Yang X, Qu J, Wang S: Primary malignant melanoma of the esophagus. Melanoma Res; 2010 Feb;20(1):59-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus.
  • Primary malignant melanoma of the esophagus is an extremely rare, but highly aggressive, tumor.
  • The prognosis for primary malignant melanoma of the esophagus remains dismal in most literatures.
  • We report here a case of primary malignant melanoma of the esophagus that was treated by surgical resection and, additionally, followed by chemotherapy.
  • The clinical features, treatment, pathological findings, and prognosis are analyzed and the literature of primary malignant melanoma of the esophagus is reviewed.
  • [MeSH-major] Esophageal Neoplasms / pathology. Melanoma / pathology
  • [MeSH-minor] Aged. Humans. Male. Prognosis. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010440.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Lee SA, Hwang JJ, Choi YH: Surgical treatment of primary malignant melanoma of the esophagus: a case report. J Korean Med Sci; 2007 Feb;22(1):149-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of primary malignant melanoma of the esophagus: a case report.
  • Primary malignant melanoma of the esophagus (PMME) is an extremely rare tumor with only scattered cases reported.
  • We report a case of PMME which was treated by surgical resection and additionally followed by chemotherapy.
  • A pigmented polypoid mass in the lower third of the esophagus was discovered, and a biopsy identified the mass as a malignant melanoma.
  • As a result, the patients was started on systemic chemotherapy treatment, which included Dacarbazine.
  • [MeSH-major] Esophageal Neoplasms / surgery. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 2001;14(3-4):241-4 [11869329.001]
  • [Cites] Ann Thorac Surg. 1973 May;15(5):463-73 [4349388.001]
  • [Cites] Cancer. 1953 Jan;6(1):1-45 [13009650.001]
  • [Cites] Int J Clin Oncol. 2005 Jun;10(3):204-7 [15990972.001]
  • [Cites] Ann Thorac Surg. 1995 Jul;60(1):217-22 [7598604.001]
  • [Cites] Am J Surg Pathol. 1987 Jan;11(1):46-52 [3789258.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jan;101(1):100-7 [1702494.001]
  • [Cites] Thorax. 1991 May;46(5):397-8 [2068703.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • (PMID = 17297270.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693554
  •  go-up   go-down


8. Fujii K, Goto A, Matsunaga Y, Hasegawa Y, Sukawa Y, Suzuki K, Yonezawa K, Abe T, Itoh A, Shinomura Y, Iimura Y, Hasegawa N, Nakamura H, Yoshida Y: [Primary malignant melanoma of the esophagus--detection of circulating tumor cells]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1539-43
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus--detection of circulating tumor cells].
  • Primary malignant melanoma of esophagus (PMME) is a rare tumor; therefore, the prognostic factors, predictive factors, and difference in biological behaviors of cutaneous melanoma and primary esophageal squamous cell carcinoma remain uncertain.
  • Although we did not adopt a standard therapeutic strategy, we performed surgical resection, chemotherapy, immunotherapy, and radiotherapy either alone or in combination; all procedures resulted in poor outcomes.
  • According to the Japanese Classification of Esophageal Cancer, the pathological stage was T1b, ly0, v0, N0, M0, stage I .
  • After subtotal esophagectomy, adjuvant chemotherapy was performed, but the malignant melanoma relapsed in the mediastinum and the patient died 10 months after diagnosis.
  • We serially monitored the patient using several new modalities, including PET/CT, metabolites of melanin: 5-S-CD, and circulating tumor cells (CTCs) by reverse transcription-polymerase chain reaction to identify the melanoma-specific gene.
  • [MeSH-major] Esophageal Neoplasms / pathology. Melanoma / pathology. Neoplastic Cells, Circulating
  • [MeSH-minor] Aged. Biopsy. Fatal Outcome. Female. Gene Expression Regulation, Neoplastic. Humans. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716882.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Archer HA, Owen WJ: Primary malignant melanoma of the esophagus. Dis Esophagus; 2000;13(4):320-3
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus.
  • This tumor, which accounts for only 0.1-0.2% of all esophageal neoplasms, is typically aggressive and disseminates early via the bloodstream and lymphatics, with only some 30% of patients surviving > 1 year after diagnosis.
  • Management of patients with esophageal melanomata is unsatisfactory, as most tumors are advanced at diagnosis, and therapeutic options are limited by inaccessibility and early dissemination of the neoplasms.
  • Poor survival rates reflect the inoperability of many tumors and the ineffectiveness of radiation and chemotherapy in eradicating advanced tumors and metastases.
  • We present two patients with primary melanoma of the esophagus and discuss the treatment options currently available.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284983.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


10. Khoury-Helou A, Lozac'h C, Vandenbrouke F, Lozac'h P: [Primary malignant melanoma of the esophagus]. Ann Chir; 2001 Jul;126(6):557-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus].
  • The primary malignant melanoma of the esophagus is a rare tumor.
  • The study aim was to report two cases, one treated by esophagectomy without thoracotomy and the other one by Lewis-Santy type esophagectomy.
  • The other one who had a cervical invaded lymph node, treated by radio-chemotherapy, is actually in complete remission 9 years after the diagnosis.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Melanoma / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Thoracotomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486540.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Gerger A, Smolle-Jüttner FM, Samonigg H, Wehrschütz M, Smolle J: Asymptomatic primary malignant melanoma of the esophagus. Onkologie; 2007 Apr;30(4):206-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic primary malignant melanoma of the esophagus.
  • BACKGROUND: Primary malignant melanoma of the esophagus is an exceedingly rare disease.
  • This tumor is typically aggressive and disseminates early via the lymphatics and the bloodstream with a mean survival time between 10 and 15 months after radical surgical resection.
  • The role of chemotherapy and immunotherapy is unclear.
  • No treatment plan for the disease has yet been established.
  • Esophagogastroscopy showed a bluishgray tumor of the esophagus, and histology revealed features consistent with malignant melanoma.
  • Immunohistochemistry revealed tumor cells strongly positive for the melanoma-specific antigen HMB45 and protein S-100, and negative for cytokeratin.
  • A proposed postoperative chemotherapy was declined by the patient.
  • Two months later, he died of bleeding into the cervical soft tissue.
  • CONCLUSION: Up to date, radical surgical resection is the main treatment.
  • Very little is known about the benefits of chemotherapy and immunotherapy.
  • However, these therapeutic modalities may play an important role in the future.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease-Free Survival. Esophagectomy. Esophagitis, Peptic / etiology. Esophagoscopy. Gastritis / etiology. Humans. Lymphatic Metastasis. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396044.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Kakudo Y, Yoshioka T, Noguchi S, Hanada M, Otsuka K, Sakayori M, Chiba N, Shibata H, Kato S, Shimodaira H, Ohori H, Takahashi S, Takahashi M, Yamaura G, Yasuda K, Ishioka C: [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Jul;33(7):969-72
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].
  • A 44-year-old man had a tumor in the lower thoracic esophagus at a health check, and was initially diagnosed as an undifferentiated carcinoma of the esophagus by the esophago-gastric endoscope.
  • Although curative chemoradiotherapy was scheduled after the diagnosis, the interim evaluation revealed that the tumor was malignant melanoma of the esophagus with right renal metastasis.
  • Since then, CVD (cisplatin, vindesine and dacarbazine) therapy, palliative radiotherapy and DAC-Tam (dacarbazine, nimustine, cisplatin and tamoxifen) therapy were carried out, but all of them proved ineffective, and multiple newly metastatic lesions appeared in liver and lymph nodes.
  • Oral intake was impossible because of progressing stricture of the esophagus.
  • As a fourth-line therapy, weekly paclitaxel therapy was started, and his oral intake was improved after the second course.
  • He received the therapy as an outpatient for four months.
  • Consequently, five courses of the therapy were performed with modest adverse effects.
  • Weekly paclitaxel therapy was reasonably safe as reported in other reports and considered to be a promising regimen for malignant melanoma of the esophagus.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Esophageal Neoplasms / drug therapy. Melanoma / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Quality of Life

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835489.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Suzuki Y, Aoyama N, Minamide J, Takata K, Ogata T: Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy. Int J Clin Oncol; 2005 Jun;10(3):204-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
  • We report a case of primary amelanotic malignant melanoma of the esophagus, an extremely rare disease.
  • A 58-year-old man was diagnosed as having middle esophageal cancer with lymph node metastasis, which was classified as esophageal cancer, Stage III:T3N1M0, by International Union Against Cancer (UICC) criteria.
  • Preoperative chemotherapy was performed, but the response assessment was no change (NC).
  • Adjuvant chemotherapy consisted of five courses of dacarbazine (DITC), nimustine (ACNU), vincristine (VCR), and interferon-beta.
  • Eleven months after the surgery, computed tomography (CT) demonstrated recurrence in the upper mediastinum.
  • The patient received chemoendocrine therapy, consisting of the first planned course of DITC, ACNU, and cisplatin (CDDP), given intravenously; and tamoxifen (TAM), given orally.
  • Subsequently with a modified regimen of this therapy he attained a complete response (CR).
  • In general, the prognosis of esophageal malignant melanoma is very poor.
  • The chemoendocrine therapy probably contributed to this outcome.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Esophagectomy. Humans. Infusions, Intravenous. Interferon-beta / administration & dosage. Male. Middle Aged. Nimustine / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1990 Mar 7;82(5):361-70 [2406452.001]
  • [Cites] Gastroenterol Jpn. 1991 Apr;26(2):209-12 [2040402.001]
  • [Cites] Jpn J Clin Oncol. 1990 Sep;20(3):286-95 [2255105.001]
  • [Cites] Thorax. 1991 May;46(5):397-8 [2068703.001]
  • [Cites] Jpn J Clin Oncol. 1998 Dec;28(12):758-61 [9879295.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jul;20(7):983-5 [6611266.001]
  • [Cites] J Immunol. 1983 Dec;131(6):2767-71 [6605988.001]
  • [Cites] Surg Today. 1993;23(9):820-4 [8219617.001]
  • [Cites] Trop Gastroenterol. 2000 Oct-Dec;21(4):185-7 [11194582.001]
  • [Cites] N Engl J Med. 1979 Nov 29;301(22):1241-2 [503125.001]
  • [Cites] Yonsei Med J. 1998 Oct;39(5):468-73 [9821797.001]
  • [Cites] N Engl J Med. 1992 Aug 20;327(8):516-23 [1635566.001]
  • [Cites] Dis Esophagus. 2000;13(4):320-3 [11284983.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1292-5 [2920358.001]
  • (PMID = 15990972.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • SNB in breast cancer was accepted as a sole and reliable diagnostic method in breast cancer by the panel of distinguished experts at the 8th international conference of primary therapy of early breast cancer 2003 in St. Gallen.
  • Albeit SNB could be shown to be safe after preoperative chemotherapy and in multicentric breast cancer, due to lack of sufficient data it is still under discussion in these cases.
  • Expedience of this procedure in other lymph node basins, along the mammaria interna vessels or in the infra- and supraclavicular region is considered to be at an investigative stage as well.
  • Detection of additional micrometastases that are found in 10-15% leads to an upgrading from N0 to N1.
  • Broad application and refurbishment led to scientific discussion of prognostic importance of micrometastases and its relevance regarding axillary dissection and adjuvant systemic treatment.
  • Findings of ongoing large prospective randomized trials like NSABP 32, Z0010 and Z0011 of the American College of Surgeons (ACOSOG), the AMAROS-Trial of the European Organisation of Research and Treatment of Cancer (EORTC) and the ALMANAC-Trial of the British Association of Surgical Oncology (BASO) will give a conclusive answer.
  • Significant improvement in morbidity and quality of life measurements could be revealed several times in unicentric and even in multicentric studies like ALMANAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


15. Sudhamshu K C, Kouzu T, Matsutani S, Hishikawa E, Nikaido T, Taro A, Hiromitsu S: Primary malignant melanoma of the esophagus treated with heavy-ion radiotherapy. J Clin Gastroenterol; 2003 Aug;37(2):151-4
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus treated with heavy-ion radiotherapy.
  • Primary malignant melanoma of the esophagus (PMME) is an uncommon but aggressive tumor with very poor prognosis.
  • There is no established treatment plan for the disease, which may be attributed to its rarity and aggressiveness.
  • Surgery is the choice of treatment in early cases.
  • Radiotherapy follows surgery, and chemotherapy has an insignificant role in its treatment.
  • Radiation with heavy ion beams is showing promising results in cancer therapy.
  • Compared to conventional radiation, it permits selective irradiation with minimal injury to the surrounding normal tissue, and treatment with a low dose within a short interval of time is possible.
  • [MeSH-major] Carbon / therapeutic use. Esophageal Neoplasms / radiotherapy. Heavy Ions / therapeutic use. Melanoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12869887.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7440-44-0 / Carbon
  •  go-up   go-down


16. Miyatani H, Yoshida Y, Ushimaru S, Sagihara N, Yamada S: Slow growing flat-type primary malignant melanoma of the esophagus treated with cap-assisted EMR. Dig Endosc; 2009 Oct;21(4):255-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Slow growing flat-type primary malignant melanoma of the esophagus treated with cap-assisted EMR.
  • We report a rare case of flat-type primary malignant melanoma of the esophagus treated with endoscopic mucosal resection (EMR).
  • A 64-year-old woman was referred for examination of a small pigmented lesion located in the mid esophagus.
  • Histopathological examination confirmed the diagnosis of primary malignant melanoma.
  • The patient was discharged without additional surgical resection and/or chemotherapy.
  • There has been no report on a slow growing esophageal melanoma.
  • [MeSH-major] Endoscopy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Melanoma / pathology. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961525.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Volpin E, Sauvanet A, Couvelard A, Belghiti J: Primary malignant melanoma of the esophagus: a case report and review of the literature. Dis Esophagus; 2002;15(3):244-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus: a case report and review of the literature.
  • The purpose of this report is to describe a new case of primary malignant melanoma of the esophagus (PMME) and to review the recent literature.
  • A pigmented polypoïd mass in the lower third of esophagus was discovered, identified by biopsy as a malignant melanoma.
  • Although characterized by an aggressive biological behavior, esophagectomy can result in a 5-year survival rate of up to 37% of cases, whereas chemotherapy, immunotherapy and radiation therapy currently have no major role in treatment.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444999.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 73
  •  go-up   go-down


18. Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H, Yamagishi H: Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol; 2007 Feb;37(2):140-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
  • Primary malignant melanoma of the esophagus (PMME) is a very rare disease with an extremely poor prognosis.
  • Surgery is currently considered its best treatment, while any other measures are ineffective.
  • We studied the effect of active specific immunotherapy using monocyte-derived dendritic cells (DCs) pulsed with the epitope peptides of melanoma-associated antigens (MAGE-1, MAGE-3) in patients with PMME after surgery, for the first time.
  • Both patients initially received radical esophagectomy with regional lymphadenectomy, followed by adjuvant chemotherapy with dacarbazine, nimustine, vincristine and interferon-alpha.
  • In the case 2 patient, immunotherapy was tried as post-operative adjuvant treatment after adjuvant chemotherapy.
  • In both patients, the ability of peripheral lymphocytes to produce IFN-gamma in vitro in response to peptide stimulation was significantly enhanced and delayed-type hypersensitivity skin test response to MAGE-3 peptide was turned positive after immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Dendritic Cells / immunology. Esophageal Neoplasms / immunology. Esophageal Neoplasms / therapy. Immunotherapy, Adoptive. Melanoma / immunology. Melanoma / therapy. Neoplasm Proteins / immunology
  • [MeSH-minor] Aged. Combined Modality Therapy. Epitopes. Esophagectomy. Humans. Male. Melanoma-Specific Antigens. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255158.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


19. Nakamura T, Ide H: [Malignant melanoma of the alimentary tract]. Gan To Kagaku Ryoho; 2003 May;30(5):619-25
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the alimentary tract].
  • We reviewed case reports of malignant melanoma in the alimentary tract and discussed the diagnosis and treatment.
  • Cases of malignant melanoma in the alimentary tract have mostly originated from the esophagus and an anorectal lesion.
  • Malignant melanoma of the alimentary tract might be more aggressive than that of the skin.
  • A combined modality treatment including progressive chemotherapy and biotherapy is expected to improve the prognosis of these patients.
  • [MeSH-major] Anus Neoplasms. Esophageal Neoplasms. Melanoma. Rectal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Nimustine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795092.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; DAV protocol
  • [Number-of-references] 39
  •  go-up   go-down


20. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • He underwent a tonsillectomy and a lymphadenectomy which both revealed melanoma metastases.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • Gastroscopy revealed bleeding from mucosal metastases of the esophagus and stomach.
  • A few weeks later the patient developed macroscopic hematuria.
  • RESULTS: This case presents common and uncommon sites of metastatic melanoma to the mucosa with the typical clinical manifestations in a single patient.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


21. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol; 2008 Mar 10;26(8):1239-46
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
  • PURPOSE: To assess the risk of secondary nonbreast cancers (SNBCs) in a recently treated population-based cohort of breast cancer patients focused on the association with treatment and prognostic implications.
  • SIRs were elevated for cancers of the esophagus, stomach, colon, rectum, lung, uterus, ovary, kidney, and bladder cancers, and for soft tissue sarcomas (STS), melanoma, non-Hodgkin's lymphoma, and acute myeloid leukemia (AML).
  • Among patients younger than 50 years, radiotherapy was associated with an increased lung cancer risk (hazard ratio [HR] = 2.31; 95% CI, 1.15 to 4.60) and chemotherapy with decreased risk for all SNBCs (HR = 0.78; 95% CI, 0.63 to 0.98) and for colon and lung cancer.
  • Among patients age 50 years and older, radiotherapy was associated with raised STS risk (HR = 3.43; 95% CI, 1.46 to 8.04); chemotherapy with increased risks of melanoma, uterine cancer, and AML; and hormonal therapy with all SNBCs combined (HR = 1.10; 95% CI, 1.01 to 1.21) and uterine cancer (HR = 1.78; 95% CI, 1.40 to 2.27).
  • [MeSH-major] Breast Neoplasms / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Netherlands / epidemiology. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Kobayashi O, Murakami H, Yoshida T, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H, Sugiyama Y, Kameda Y: Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center. World J Surg; 2004 Jun;28(6):548-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors included one each of squamous cell carcinoma of the esophagus, signet-ring cell carcinoma of the breast, large-cell or small-cell carcinoma of the lung, renal cell carcinoma, hepatocellular carcinoma, squamous cell or epidermoid carcinoma of the uterus, and melanoma.
  • Five patients were treated by chemotherapy with no apparent survival benefit.
  • A median survival after MGT diagnosis was 170 days (range 16-892 days) for all cases, 384 days for those who underwent gastrectomy (n = 6), and 27 days for those without active treatment (n = 3) (p = 0.002).

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):152-5 [7959258.001]
  • [Cites] Int J Clin Pract. 2002 Oct;56(8):623-5 [12425377.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1581-4 [11149006.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] JAMA. 1974 Aug 12;229(7):825-6 [4407823.001]
  • [Cites] Am J Surg. 1991 Sep;162(3):208-11 [1718180.001]
  • [Cites] Indian J Gastroenterol. 1992 Apr;11(2):88 [1428039.001]
  • [Cites] Radiology. 1972 Oct;105(1):1-11 [5066554.001]
  • [Cites] Dig Dis Sci. 1990 Nov;35(11):1421-5 [2226104.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Mar;123(3):512-21 [1124830.001]
  • [Cites] J Gastroenterol. 1994 Feb;29(1):71-5 [7515309.001]
  • [Cites] Gastrointest Endosc. 2000 Aug;52(2):273-5 [10922110.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2235-41 [4052968.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Can J Surg. 1962 Oct;5:438-41 [13954414.001]
  • [Cites] Acta Oncol. 1993;32(4):459-60 [8396398.001]
  • [Cites] Acta Chir Belg. 2000 Sep-Oct;100(5):228-30 [11143327.001]
  • [Cites] Thorac Cardiovasc Surg. 1993 Oct;41(5):318-20 [8303703.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Clin Gastroenterol. 1998 Mar;26(2):153-4 [9563931.001]
  • [Cites] Am J Surg. 1960 Jan;99:94-6 [13814449.001]
  • [Cites] Endoscopy. 1996 Feb;28(2):262 [8739747.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):170-2 [6274500.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):566-7 [12297779.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):495-500 [7951861.001]
  • [Cites] Am J Gastroenterol. 1985 Jan;80(1):67-9 [3966457.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):363-5 [11474262.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1209-12 [12168927.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • (PMID = 15366743.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • Primary neoplasms include breast cancer (n=11), colorectal cancer (n=7), lung cancer (n=6), prostate cancer (n=5), nasopharyngeal cancer (n=5), head and neck cancer (n=3), thyroid cancer (n=2), liver cancer (n=2), esophagus cancer (n=1), bladder cancer (n=1), retroperitoneum cancer (n=1), medulloblastoma (n=1), cervical cancer (n=1), ovarian cancer (n=1), malignant melanoma (n=1).
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


24. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: [Sentinel node biopsy in breast cancer: techniques and indications]. Wien Klin Wochenschr; 2005 Feb;117(4):121-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • SNB in breast cancer was accepted as a sole and reliable diagnostic method in breast cancer from the panel of distinguished experts at the 8th international conference of primary therapy of early breast cancer 2003 in St. Gallen.
  • Albeit SNB could be shown to be safe after preoperative chemotherapy and in multicentric breast cancer, due to lack of sufficient data it is still under discussion in these cases.
  • Expedience of this procedure in other lymph node basins, along the mammaria interna vessels or in the infra- and supraclavicular region is considered to be at an investigative stage as well.
  • Detection of additional micrometastases that are found in 10-15% leads to an upgrading from N0 to N1.
  • Broad application and refurbishment led to scientific discussion of prognostic importance of micrometastases and its relevance according axillary dissection and adjuvant systemic treatment.
  • Findings of ongoing large prospective randomized trials like NSABP 32, Z0010 and Z0011 of the American College of Surgeons (ACOSOG), the AMAROS-Trial of the European Organisation of Research and Treatment of Cancer (EORTC) and the ALMANAC-Trial of the British Association of Surgical Oncology (BASO) will give a conclusive answer.
  • Significant improvement in morbidity and quality of life measurements could be revealed several times in unicentric and even in muticentric studies like ALMANAC.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847190.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 73
  •  go-up   go-down


25. Berber E, Ari E, Herceg N, Siperstein A: Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc; 2005 Dec;19(12):1613-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is increasing experience with laparoscopic radiofrequency ablation for the treatment of patients with hepatic metastasis from colorectal and neuroendocrine cancer and those with hepatocellular cancer.
  • Little is known about the outcomes for patients with other tumor types.
  • Among these, 53 patients (10%) had cancers other than the colorectal, neuroendocrine, or hepatocellular types including sarcoma (n = 18), breast cancer (n = 10), esophagus cancer (n = 4), melanoma (n = 4), lung cancer (n = 3), ovarian cancer (n = 2), pancreas cancer (n = 2), unknown primary cancer (n = 2), cholangiocarcinoma (n = 2), rectal squamous cancer (n = 2), renal cancer (n = 2), papillary thyroid cancer (n = 1), and hemangioendothelioma (n = 1).
  • Unlike the criteria for treatment of the more usual tumor types, these patients had a diagnosis of liver-exclusive disease, as diagnosed by preoperative imaging.
  • They also had failed chemotherapy.
  • RESULTS: The 53 patients underwent ablation of 192 lesions, with 8 patients undergoing repeat treatment.
  • CONCLUSION: Laparoscopic radiofrequency ablation can safely and effectively treat hepatic metastasis of these unusual tumor types.
  • The authors believe that this heterogeneous group of patients, selected for their unusual presentation of liver-exclusive disease, may benefit from cytoreduction of their tumor by laparoscopic radiofrequency ablation when other treatment methods have failed.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):201-5 [9496513.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1009-14 [10551746.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):72-5 [7740813.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):151-5 [9834411.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):950-5 [11485537.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):379-80 [11352313.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Oncologist. 2003;8(3):241-51 [12773746.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Vasc Interv Radiol. 1999 Jul-Aug;10(7):907-16 [10435709.001]
  • [Cites] J Surg Res. 1999 Nov;87(1):114-21 [10527712.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Thorac Surg. 2003 Jul;76(1):291-3 [12842567.001]
  • (PMID = 16247574.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


27. Tsunoo H, Komura S, Ohishi N, Akiyama S, Kasai Y, Ito K, Nakao A, Yagi K: Effects of interferon-beta in combination with 5-fluorouracil on the growth of esophageal cancer cells in vitro. Anticancer Res; 2001 Sep-Oct;21(5):3301-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of interferon-beta in combination with 5-fluorouracil on the growth of esophageal cancer cells in vitro.
  • The possible antiproliferative potency of human recombinant interferon-beta (hIFN-beta) towards ten human esophageal cancer cell lines was examined in comparison with the activity of the factor towards human malignant melanoma cell lines.
  • The cell growth of esophageal cancer cell lines was inhibited by hIFN-beta in a dose- and time- dependent manner.
  • Under the same culture conditions, the melanoma cell lines tested differed markedly in their sensitivity to hIFN-beta.
  • When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced.
  • All these data suggest that combination therapy with hIFN-beta and the anticancer drug 5-FU would be beneficial for the treatment of carcinoma of the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Interferon-gamma / pharmacology
  • [MeSH-minor] Cell Division / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Drug Synergism. Fluorouracil / administration & dosage. Growth Inhibitors / administration & dosage. Growth Inhibitors / pharmacology. Humans. Recombinant Proteins. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11848487.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Growth Inhibitors; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE: Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol; 2009 Feb;63(3):451-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-one patients received 42 cycles of treatment over five dose levels.
  • Limited accumulation of DHA-paclitaxel or paclitaxel occurred with weekly treatment.
  • Of the 19 patients evaluable for response, three patients with esophageal, melanoma and colon carcinoma had stable disease for 11, 16, and 17 weeks, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromatography, Liquid. Docosahexaenoic Acids / administration & dosage. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Sensitivity and Specificity. Tandem Mass Spectrometry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414864.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 25167-62-8 / Docosahexaenoic Acids; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Kawada K, Kawano T, Nagai K, Nishikage T, Nakajima Y, Tokairin Y, Ogiya K, Tanaka K, Iwai T: Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival. Gastrointest Endosc; 2007 Aug;66(2):408-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Interferon-beta / administration & dosage. Melanoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Disease-Free Survival. Esophagoscopy. Female. Humans. Injections, Intralesional. Middle Aged. Nimustine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643724.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; DAV protocol
  •  go-up   go-down


30. Uetsuka H, Naomoto Y, Fujiwara T, Shirakawa Y, Noguchi H, Yamatsuji T, Haisa M, Matsuoka J, Gunduz M, Takubo K, Tanaka N: Primary malignant melanoma of the esophagus: long-term survival following pre- and postoperative adjuvant hormone/chemotherapy. Dig Dis Sci; 2004 Oct;49(10):1646-51
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the esophagus: long-term survival following pre- and postoperative adjuvant hormone/chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Esophageal Neoplasms / mortality. Esophageal Neoplasms / surgery. Esophagectomy. Interferon-beta / therapeutic use. Melanoma / drug therapy. Melanoma / mortality. Tamoxifen / therapeutic use
  • [MeSH-minor] Adjuvants, Immunologic. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1990 Jan;43(1):82-3 [2312756.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):553-6 [1537621.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2528-34 [7296502.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1961 Dec;70:1140-7 [13918151.001]
  • [Cites] Am J Gastroenterol. 1989 Dec;84(12):1475-81 [2688398.001]
  • [Cites] Thorax. 1991 May;46(5):397-8 [2068703.001]
  • [Cites] Jpn J Clin Oncol. 1998 Dec;28(12):758-61 [9879295.001]
  • [Cites] Jpn J Clin Oncol. 1991 Aug;21(4):306-13 [1942560.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):1018-22 [8253520.001]
  • [Cites] Int Adv Surg Oncol. 1980;3:73-109 [6926744.001]
  • [Cites] Ann Thorac Surg. 1973 May;15(5):463-73 [4349388.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Histopathology. 1992 Jan;20(1):77-9 [1737631.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):65-9 [1642409.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1571-6 [8453625.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Ann Chir. 2001 Jul;126(6):557-60 [11486540.001]
  • (PMID = 15573920.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 77238-31-4 / Interferon-beta
  • [Number-of-references] 18
  •  go-up   go-down


31. Mamori S, Kahara F, Ohnishi K, Takeda A, Higashida A, Ashida C, Yamada H: Survivin expression in primary malignant melanoma of the esophagus. Scand J Gastroenterol; 2009;44(12):1497-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in primary malignant melanoma of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Melanoma / drug therapy. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / genetics. Biopsy. Cysteine Proteinase Inhibitors / genetics. Humans. Imidazoles / therapeutic use. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Naphthoquinones / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883277.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Cysteine Proteinase Inhibitors; 0 / Imidazoles; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Naphthoquinones; 0 / YM 155
  •  go-up   go-down


32. Sakamoto H, Uedo N, Iishi H, Higashino K, Ishihara R, Mitani K, Narahara H, Tatsuta M, Mano M, Ishiguro S: Treatment of primary malignant melanoma of the esophagus with endoscopic injection of interferon-beta combined with systemic chemotherapy: a case report. Gastrointest Endosc; 2003 May;57(6):773-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary malignant melanoma of the esophagus with endoscopic injection of interferon-beta combined with systemic chemotherapy: a case report.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Esophageal Neoplasms / drug therapy. Interferon-beta / administration & dosage. Melanoma / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Endoscopy. Female. Humans. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12739558.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 77238-31-4 / Interferon-beta
  •  go-up   go-down






Advertisement